Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. No abstract available.

PMID:
32209563
2.

[Typhoid and paratyphoid fever].

Trawinski H, Wendt S, Lippmann N, Heinitz S, von Braun A, Lübbert C.

Z Gastroenterol. 2020 Feb;58(2):160-170. doi: 10.1055/a-1063-1945. Epub 2020 Feb 12. Review. German.

PMID:
32050286
3.

Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.

Buzibye A, Musaazi J, von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, Fehr J, Lamorde M, Gutteck U, Muller D, Sowinski S, Reynolds SJ, Castelnuovo B.

AIDS Res Ther. 2019 Dec 6;16(1):39. doi: 10.1186/s12981-019-0255-x.

4.

Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination.

Bradt V, Malafa S, von Braun A, Jarmer J, Tsouchnikas G, Medits I, Wanke K, Karrer U, Stiasny K, Heinz FX.

NPJ Vaccines. 2019 Sep 6;4:38. doi: 10.1038/s41541-019-0133-5. eCollection 2019.

5.

Schistosoma and Other Relevant Helminth Infections in HIV-Positive Individuals-an Overview.

von Braun A, Trawinski H, Wendt S, Lübbert C.

Trop Med Infect Dis. 2019 Apr 12;4(2). pii: E65. doi: 10.3390/tropicalmed4020065. Review.

6.

Tuberculosis in Pregnancy - a Summary.

Wolf B, Krasselt M, de Fallois J, von Braun A, Stepan H.

Geburtshilfe Frauenheilkd. 2019 Apr;79(4):358-365. doi: 10.1055/a-0774-7924. Epub 2019 Jan 8.

7.

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Erratum in: Antimicrob Agents Chemother. 2020 Mar 24;64(4):.

8.

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.

Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M.

Clin Pharmacol Ther. 2019 Aug;106(2):450-457. doi: 10.1002/cpt.1403. Epub 2019 Mar 29.

PMID:
30779340
9.

Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options.

Baumann A, Musaazi J, Kambugu A, Kälin M, Weissberg D, Ssemwanga D, Fehr J, Castelnuovo B, Sekaggya-Wiltshire C, von Braun A.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):481-487. doi: 10.1097/QAI.0000000000001943.

PMID:
30633041
10.

Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.

Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study.

J Antimicrob Chemother. 2019 Feb 1;74(2):468-472. doi: 10.1093/jac/dky436.

PMID:
30476115
11.

Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort.

Weissberg D, Mubiru F, Kambugu A, Fehr J, Kiragga A, von Braun A, Baumann A, Kaelin M, Sekaggya-Wiltshire C, Kamya M, Castelnuovo B.

PLoS One. 2018 Nov 1;13(11):e0206796. doi: 10.1371/journal.pone.0206796. eCollection 2018.

12.

High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.

von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C.

J Antimicrob Chemother. 2019 Jan 1;74(1):135-138. doi: 10.1093/jac/dky379.

PMID:
30239753
13.

[New Guidelines and Data to Clostridium difficile - What's New?]

Lübbert C, Lippmann N, von Braun A.

Dtsch Med Wochenschr. 2018 Jun;143(11):787-792. doi: 10.1055/a-0585-9595. Epub 2018 May 28. German.

PMID:
29807377
14.

HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic.

von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Günthard HF, Castelnuovo B, Fehr J, Kambugu A.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):566-573. doi: 10.1097/QAI.0000000000001717.

15.

[Treatment of acute and recurrent Clostridium difficile infections : What is new?]

von Braun A, Lübbert C.

Internist (Berl). 2018 May;59(5):505-513. doi: 10.1007/s00108-018-0401-x. Review. German.

PMID:
29536125
16.

Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS.

Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179.

17.

Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.

Sekaggya-Wiltshire C, Castelnuovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, Kambugu A.

BMJ Open. 2017 Sep 18;7(9):e014679. doi: 10.1136/bmjopen-2016-014679.

18.

Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.

Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, Kambugu A, Byakika-Kibwika P, Lamorde M, Castelnuovo B, Fehr J, Kamya MR.

J Antimicrob Chemother. 2017 Apr 1;72(4):1172-1177. doi: 10.1093/jac/dkw534.

19.

Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.

von Braun A, Sekaggya-Wiltshire C, Scherrer AU, Magambo B, Kambugu A, Fehr J, Castelnuovo B.

AIDS Res Ther. 2017 Jan 5;14(1):1. doi: 10.1186/s12981-016-0128-5.

20.

Challenges in achieving a target international normalized ratio for deep vein thrombosis among HIV-infected patients with tuberculosis: a case series.

Sekaggya C, Nalwanga D, Von Braun A, Nakijoba R, Kambugu A, Fehr J, Lamorde M, Castelnuovo B.

BMC Hematol. 2016 Jun 4;16:16. doi: 10.1186/s12878-016-0056-6. eCollection 2016.

21.

Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.

Meloni M, Corti N, Müller D, Henning L, Gutteck U, von Braun A, Weber R, Fehr J.

Swiss Med Wkly. 2015 Dec 23;145:w14223. doi: 10.4414/smw.2015.14223. eCollection 2015.

22.

Reduced naïve CD8(+) T-cell priming efficacy in elderly adults.

Briceño O, Lissina A, Wanke K, Afonso G, von Braun A, Ragon K, Miquel T, Gostick E, Papagno L, Stiasny K, Price DA, Mallone R, Sauce D, Karrer U, Appay V.

Aging Cell. 2016 Feb;15(1):14-21. doi: 10.1111/acel.12384. Epub 2015 Oct 15.

23.

'If at first you don't succeed, try again'. Looking beyond the initial results of a failed tuberculosis diagnosis.

von Braun A, Sekaggya C, Henning L, Nakijoba R, Kambugu A, Fehr J, Castelnuovo B.

Public Health Action. 2015 Sep 21;5(3):170-2. doi: 10.5588/pha.15.0029.

24.

Do high-touch surfaces in public spaces pose a risk for influenza transmission? A virologic study during the peak of the 2009 influenza A(H1N1) pandemic in Geneva, Switzerland.

von Braun A, Thomas Y, Sax H.

Am J Infect Control. 2015 Dec 1;43(12):1372-3. doi: 10.1016/j.ajic.2015.07.012. Epub 2015 Aug 17. No abstract available.

PMID:
26293999
25.

New onset of kaposi sarcoma in a human immunodeficiency virus-1-infected homosexual man, despite early antiretroviral treatment, sustained viral suppression, and immune restoration.

von Braun A, Braun DL, Kamarachev J, Günthard HF.

Open Forum Infect Dis. 2014 Apr 17;1(1):ofu005. doi: 10.1093/ofid/ofu005. eCollection 2014 Mar.

26.

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda.

Wiltshire CS, Lamorde M, Scherrer A, Musaazi J, Corti N, Allan B, Nakijoba R, Nalwanga D, Henning L, Von Braun A, Okware S, Castelnuovo B, Kambugu A, Fehr J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19585. doi: 10.7448/IAS.17.4.19585. eCollection 2014.

27.

Postsurgical wound infections due to rapidly growing mycobacteria in Swiss medical tourists following cosmetic surgery in Latin America between 2012 and 2014.

Maurer F, Castelberg C, von Braun A, Wolfensberger A, Bloemberg G, Bottger E, Somoskovi A.

Euro Surveill. 2014 Sep 18;19(37). pii: 20905. No abstract available.

28.

[Antiretroviral therapy].

von Braun A, Furrer H, Battegay M, Calmy A, Cavassini M, Vernazza P, Bernasconi E, Weber R, Günthard HF.

Ther Umsch. 2014 Aug;71(8):461-8. doi: 10.1024/0040-5930/a000538. Review. German.

PMID:
25093310
29.

[HIV infection and antiretroviral therapy: basic principles of treatment and impacts on other therapies].

von Braun A, Günthard H.

Praxis (Bern 1994). 2013 Jan 2;102(1):5-13; quiz 14-5. doi: 10.1024/1661-8157/a001156. Review. German. No abstract available.

30.

Severe thyrotoxicosis: a rare cause of acute delirium.

von Braun A, Bühler A, Yuen B.

Intern Emerg Med. 2012 May;7 Suppl 1:S27-8. doi: 10.1007/s11739-011-0572-0. Epub 2011 Mar 31. No abstract available.

Supplemental Content

Loading ...
Support Center